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Abstract
Background: Combining meningococcal vaccination with routine immunization in infancy may reduce the burden of
meningococcal meningitis, especially in the meningitis belt of Africa. We have evaluated the immunogenicity, persistence of
immune response, immune memory and safety of an investigational DTPw-HBV/Hib-MenAC conjugate vaccine given to
infants in Northern Ghana.
Methods and Findings: In this phase II, double blind, randomized, controlled study, 280 infants were primed with DTPw-
HBV/Hib-MenAC or DTPw-HBV/Hib vaccines at 6, 10 and 14 weeks of age. At 12 months of age, children in each group
received a challenge dose of serogroup A+C polysaccharides. Antibody responses were assessed pre, and one month-post
dose 3 of the priming schedule and pre and 1 month after administration of the challenge dose. One month post-dose 3,
87.8% and 88.2% of subjects in the study group had bactericidal meningococcal serogroup A (SBA-MenA) and
meningococcal serogroup C (SBA-MenC) antibody titres $1:8 respectively. Seroprotection/seropositivity rates to the 5
antigens administered in the routine EPI schedule were non-inferior in children in the study group compared to those in the
control group. The percentages of subjects in the study group with persisting SBA-MenA titres $ 1:8 or SBA-MenC titres
$1:8 at the age of 12 months prior to challenge were significantly higher than in control group (47.7% vs 25.7% and 56.4%
vs 5.1% respectively). The administration of 10 mg of serogroup A polysaccharide increased the SBA-MenA GMT by 14.0-fold
in the DTPW-HBV/HibMenAC-group compared to a 3.8 fold increase in the control-group. Corresponding fold-increases in
SBA-MenC titres following challenge with 10 mg of group C polysaccharide were 18.8 and 1.9 respectively. Reactogenicity
following primary vaccination or the administration of the challenge dose was similar in both groups, except for swelling
(Grade 3) after primary vaccination which was more frequent in children in the vaccine than in the control group (23.7%;
95%CI [19.6–28.1] of doses vs 14.1%; 95% CI [10.9–17.8] of doses). Fifty-nine SAEs (including 8 deaths), none of them related
to vaccination, were reported during the entire study.
Conclusions: Three dose primary vaccination with DTPw-HBV/Hib-MenAC was non-inferior to DTPw-HBV/Hib for the 5
common antigens used in the routine EPI schedule and induced bactericidal antibodies against Neisseria meningitidis of
serogroups A and C in the majority of infants. Serogroup A and C bactericidal antibody levels had fallen below titres
associated with protection in nearly half of the infants by the age of 12 months confirming that a booster dose is required
at about that age. An enhanced memory response was shown after polysaccharide challenge. This vaccine could provide
protection against 7 important childhood diseases (including meningococcal A and C) and be of particular value in
countries of the African meningitis belt.
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Introduction
Meningococcal disease affects up to 1.2 million people
worldwide each year with a death toll estimated at around 135,
000 [1]. The highest burden occurs in the ‘‘meningitis belt’’ of sub-
Saharan Africa which extends across the Sahel and sub-Sahel from
Senegal to Ethiopia. Meningitis epidemics have also been reported
in Africa outside the meningitis belt (Morocco, Rwanda, Burundi,
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these regions, an estimated 250, 000 persons become infected each
year [5] with a mortality rate averaging 10% but which can reach
30% during epidemics; 10–15% of survivors have neurological
sequelae [1,3,6,7]. Children between 3 months and 5 years of age
have the highest risk of contracting the disease but during
epidemics, older children and young adults are vulnerable [4,8].
During inter-epidemic years, incidence and the case fatality rate
are high among infants [8]. The treatment of choice in Africa
during epidemics is parenteral chloramphenicol or third-genera-
tion cephalosporins, such as ceftriaxone [9,10].
In Africa, serogroup A Neisseria meningitidis is still responsible for
most meningococcal epidemics, while group C meningococci have
caused some outbreaks [3]. An outbreak due to serogroup group
W135 meningococci occurred recently among Hajj pilgrims [11],
and W135 epidemics or outbreaks have also been reported in
Niger [12], Burkina Faso [13] and Chad [14]. Cases of W135
disease have now been detected in nearly all countries of the
‘‘meningitis belt’’ including Ghana [7,15]. A serogroup X
outbreak was reported in Niger in 2006 [16].
Polysaccharide vaccines against serogroup A and C meningoc-
cocal infections have existed since the late 1960s and are readily
accessible and affordable. Following the recent emergence of the
W-135 serogroup in Africa, a trivalent polysaccharide ACW-135
vaccine has been developed and made available at reasonable cost
[4,7]. There is no vaccine available to protect against serogroup X
meningococci. Polysaccharide vaccines, used mainly for reactive
mass vaccination during epidemics, are poorly immunogenic in
children under 2 years of age (except for serogroup A), induce
short-lived protection (3–5 years) in children, and have a limited
ability to reduce nasopharyngeal carriage and induce herd
immunity [7]. Although mass vaccination with polysaccharide
vaccines can prevent up to 70% of cases [17,18] if implemented at
the onset of an outbreak such high levels of protection are rarely
achieved and widespread use of polysaccharide vaccines has not
prevented continuing epidemics in Africa [4,19]. Meningococcal
polysaccharide vaccines conjugated to immunogenic proteins (i.e.
diphtheria toxoid, tetanus toxoid) are more immunogenic in
infants than polysaccharide vaccines, and induce immunological
memory and herd immunity [20,21]. Meningococcal serogroup C
conjugate vaccines are now available and have proved to be highly
immunogenic, even in young infants. They reduce carriage and
induce herd immunity [22,23]. In the United Kingdom, serogroup
C conjugate vaccines have proved to be highly effective in
preventing invasive serogroup C meningococcal disease in all age
groups but a booster dose is recommended in the second year of
life to optimize the protection afforded by primary vaccination of
infants [22]. Since 2005, a tetravalent ACWY conjugate vaccine
has been available in the United States for use in subjects aged
11 years and older [24].
Two meningococcal A+C conjugate vaccines, employing
diphtheria toxoid or a mutant of diphtheria toxoid (CRM197)
as a carrier protein, have shown immunogenicity in infants
during clinical studies in Africa [25,26], but these vaccines were
not taken forward into commercial development. The MenA
component of one of them failed to demonstrate induction of
immune memory [27]. In subjects who received a booster at
2 years of age, the immune response was long lasting (active up to
5 years of age) and superior to that obtained with polysaccharide
vaccines [28].
The optimum schedule of administration of conjugate vaccines
is not yet well defined. This was highlighted in a study that showed
that 2 doses of conjugate Men A/C vaccine given at 2 and
6 months of age induced a lower MenC antibody response than a
single dose given at 6 months of age [26]. The Meningitis Vaccine
Project is developing a monovalent serogroup A meningococcal
conjugate vaccine to be used in mass vaccination [29]. To offer
African infants a broader protection against the most prevalent
forms of meningococcal disease, GlaxoSmithKline (GSK) Biolog-
icals has developed a combined Haemophilus influenzae type b,
meningococcal serogroup A and C (Hib-MenAC) conjugate
vaccine to be mixed extemporaneously with its diphtheria, tetanus,
whole-cell pertussis, hepatitis B (DTPw-HBV) vaccine. Such a
combination has already been shown to have a good reactogenic-
ity and immunogenicity profile, including induction of immune
memory, in the Philippines [30]. It can be given within the routine
immunization calendar and thus has the potential to achieve high
vaccine coverage.
The aim of the present study was to evaluate the immunogenicity,
reactogenicity and safety of this combination vaccine when given to
infants as a three-dose primary vaccination (following the EPI
schedule) in an area within the African meningitis belt.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
The primary objectives of the study (study ID:759346/009 &
104430; ISRCTN:35754083) were to demonstrate that the
DTPw-HBV/Hib-MenAC candidate vaccine is non-inferior to
the currently used DTPw-HBV/Hib vaccine with respect to the
immunogenicity of the five antigens shared between the two
vaccines, and to demonstrate the immunogenicity of the MenA
and MenC conjugate antigen components of the new candidate
vaccine.
Prior to the launch of the study, the protocol and study
materials were approved by the Ghana Health Service Ethical
Review Committee, the London School of Hygiene & Tropical
Medicine Ethics Committee, Institutional Review Board of the
Navrongo Health Research Centre and the World Health
Organization Research Ethics Review Committee (ERC). The
trial was conducted in accordance with ICH GCP guidelines. At
the time of enrollment, the HIV prevalence amongst antenatal
attendants was 2.8% [31].
Study area
The study was carried out in the Kassena-Nankana District,
Upper East Region, Ghana during the period between June 2004
and October 2005. The Kassena-Nankana District lies in a region
of wooded Guinea savanna and has a seasonal climate with a long
dry season and a short rainy season. It is situated within the
African meningitis belt and experienced a large epidemic of
serogroup A meningococcal disease in 1996/1997. The ecology of
pharyngeal colonization with N. meningitidis has been studied in
detail in the area since 1998 [32]. Serogroup A/C meningococcal
polysaccharide vaccine has been used widely in the region since
1997. None of the study infants had received a meningococcal
vaccine prior to entering the study but some of their mothers had
been vaccinated (see below).
Study participants
Male and female infants who had a birth weight $2 kg (when
known) and who were 6 to 8 weeks of age at the time of first
vaccination were enrolled in the study provided that they had
none of the following exclusion criteria: (1) malnutrition, (2) a
history of neurological disorder or immunodeficiency, (3) a family
history of immunodeficiency, (4) a history of receiving immuno-
DTPw-HBV/Hib-MenAC vaccine
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protocol, (6) exposure, by direct contact, to diphtheria (D), tetanus
(T), pertussis (Pw), hepatitis B (HBV), Haemophilus influenzae type b
(Hib), and/or meningococcal disease since birth. Witnessed,
written, informed consent was obtained from the parents or
guardians of each infant before enrolment.
Study design
The study was controlled and double-blind. Infants were
allocated to either DTPw-HBV/Hib-MenAC (study group) or
DTPw-HBV/Hib (control group), following a randomization-
blocking scheme (1:1 ratio, block 4, no covariates were used for
blocking).
Vaccination
The study vaccine (DTPw-HBV/Hib-MenAC) comprised one
vial of Hib-MenAC, containing 5 mg of each polysaccharide
conjugate, reconstituted extemporaneously with two vials of
DTPw-HBV; only half of the mixture was administered as each
vial contained two doses. The control vaccine was the commer-
cially available DTPw-HBV/Hib vaccine Tritanrix
TM-HBV/Hi-
berix
TM (GSK Biologicals). Three doses of study or control vaccine
were injected intramuscularly, the first at 6 weeks (range 6–
8 weeks) of age, the subsequent ones at 4 week intervals (range 28–
42 days). When aged 12 months, each child received a challenge
dose of 10 mg of meningococcal polysaccharides A and C, given as
one fifth of a dose of GSK Biologicals’ Mencevax AC
TM that
contains 50 mg of each polysaccharide.
To comply with the Ghanaian routine immunization schedule
[33], infants received Bacille Calmette-Gue ´rin (BCG) and oral
polio vaccine (OPV) at birth (or up to 2 weeks before the subject’s
first visit). OPV could be given concomitantly with the study
vaccines or at any time during the study. Measles and yellow fever
vaccines were administered to each study infant at 9 months of
age. Tritanrix-HepB, Hiberix and Mencevax AC are trademarks of the
GlaxoSmithKline group of companies.
Reactogenicity and safety
Subjects were monitored for any immediate reactions to
vaccination for 30 minutes after each injection. Field workers,
blinded to study group, visited subjects at their home on the day of
vaccine administration and on the 3 subsequent days to record on
diary cards body temperature and any local or general adverse
events. The occurrence of pain, swelling, fever, drowsiness, loss of
appetite, or irritability was solicited from the parents or guardians.
Any adverse events occurring within 30 days after administration
of each dose of vaccine were also recorded on diary cards and
reviewed by the investigators. Serious adverse events (SAEs),
defined as any hospitalization, death or life-threatening medical
condition, were recorded throughout the study and reviewed by
the Ghanaian National Ethics Committee as well as by the
Institutional Review Board of the Navrongo Health Research
Centre. An Independent Data Monitoring Committee (IDMC)
reviewed the safety and reactogenicity data after the first dose had
been given to the first 60 infants; the IDMC also reviewed all SAEs
on a quarterly basis.
Immunogenicity
Four blood samples (3.5 ml) were collected from all subjects at the
following times-immediately prior to administration of the first dose
of study vaccine, one month after the third dose, immediately before
the polysaccharide challenge and one month afterwards. Frozen
samples were shipped to GSK Biologicals for serological assays.
Serogroup A and serogroup C bactericidal antibody titres (SBA-
MenA and SBA-MenC) were determined using a well standardized
assay which utilizes baby rabbit serum as the source of complement
(Pel-Freeze Incorporated, Rodgerson, AZ, USA) [34]. The strains
usedintheassayswereF8238forMenAandC11forMenC.Titresof
bactericidal antibody were expressed as the reciprocal of the dilution
resulting in 50% killing after 60 minutes incubation. A titre of 1:8 or
greater was used to define seropositivity. A SBA titre of at least 1:8 has
been validated as protective against serogroup C invasive meningo-
coccal disease [35]. For serogroup A meningococcal disease, no
protective SBA titre has yet been validated but an anti-PSA IgG
concentration of 2 mg/ml (measured by Radioactive Antigen Binding
Assay: RABA) has been shown to be associated with protection [36].
In this study, IgG antibodies to meningococcal polysaccharides A and
C were measured by an ELISA (cut-off for positivity=0.30 mg/ml)
[37]. Antibodies to diphtheria toxoid (D)(cut-off for positivity=0.1U/
ml), tetanus toxoid (T) (cut-off for positivity=0.1IU/ml), inactivated
Bordetella pertussis (whole cell) (BPT) (cut-off for positivity=15 EL.U/
ml), to hepatitis B surface antigen (HBV) (cut-off for positivity=10
mIU/ml) and to Hib polyribose phosphate (PRP) (cut-off for
positivity=0.15 mg/ml) were quantified using standardized ELISAs
at GSK Biologicals, Rixensart, Belgium.
Post-vaccination serum samples with ELISA anti-D antibody
concentrations ,0.1 IU/ml were re-tested using a VERO cell
neutralization assay [38]. The cut-off for the VERO cell assay
associated with protection is 0.016 IU/ml. Subjects with antibody
response$the assay cut-off were considered protected against Hib-
disease, diphtheria, tetanus or hepatitis B.
Statistical analyses
To cope with the multiplicity of study objectives, the pre-set
criteria for meeting the study objectives were assessed sequentially.
The sample size for the primary According-To-Protocol (ATP)
cohort for immunogenicity comparisons was set at 280 enrolled
subjects allowing for 60 drop-outs. A total of 220 evaluable
subjects provided a study cumulative power to meet each criterion
of co-primary endpoints individually (each individual power was at
least 84%, except for anti-PRP for which it was 79.8%).
Data analysis was performed at GSK Biologicals using SAS
software-Proc Plan (version 8.2) and StatXact (version 5.0). The
primary immunogenicity analysis was performed on the initial
ATP cohort, comprising all vaccinated subjects complying with the
protocol and for whom assay results were available for antibodies
against at least one study vaccine antigen component at one
month post administration of vaccine dose 3. The analysis of
persistence was performed on the ATP cohort for persistence,
which comprised children vaccinated with the 3 primary vaccine
doses and the polysaccharide challenge who had not received
immunoglobulin or blood transfusion. The post-challenge ATP
immunogenicity analysis was performed on children who
complied with the protocol for the challenge part of the study
and for whom assay results were available for antibodies against at
least one study vaccine antigen one month post the challenge dose.
Immune responses were expressed as geometric mean antibody
concentrations (GMC) for antibodies detected by ELISA, or as
geometric mean titres (GMT) for antibodies detected by serum
bactericidal activity (SBA). In an exploratory way, the non-
overlapping of the 95% CIs between the 2 groups was used as an
indicator of a statistically significant difference. The primary
objective was met if the differences between the groups were less
than 10% (lower limit [LL] of the 95% confidence interval [CI] of
difference between study population minus control more than
210%) in terms of seroprotection rate for D, T, HBV, and Hib
antibodies, or if UL of the group ratio GMC was below 1.5 for
DTPw-HBV/Hib-MenAC vaccine
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titres of at least 1:8 was .80% (for both serogroups A and C).
All 280 vaccinated subjects who received at least one primary
vaccination dose of study vaccine (total vaccinated cohort) were
included in the analysis of safety. The incidences of solicited
symptoms, as well as of those graded 3 (i.e. preventing daily
activity, or swelling .30mm, or rectal fever .40uC), within the 4-
day follow-up period were tabulated over the whole primary
vaccination course (i.e. per dose), with exact 95% CIs. The
incidence of unsolicited symptoms during the 31-day follow-up
period after administration of each dose of vaccine was calculated
using the standard terminology of the Medical Dictionary for
Regulatory Activities (MedDRAH) primary system organ class and
primary term. Reactogenicity and safety after the challenge dose of
polysaccharide were assessed similarly. Only unsolicited symptoms
and Serious Adverse Events are discussed in this paper. Serious
adverse events were described according to the following study
period: from enrolment up to one month after the third dose of the
primary vaccination series, from one month after the third dose of
vaccine up to the time of the challenge dose and for the period of
one month after the challenge dose had been given.
Results
Study population
Two hundred and eighty of the 418 infants whose parents
responded to an invitation to join the study were identified as
eligible and were enrolled (Figure 1): 6 did not complete the study
(4 in the study group due to SAEs and 1 subject in each study
group who was lost to follow-up). Thus, 97.8% completed the
primary vaccination phase of the study. At enrolment, the
demographic profiles of infants in each group were comparable
with no significant differences between groups (Table 1). Two
hundred and fifty-nine children were included in the analysis of
immunogenicity one month after the third dose. Of the 260
children who were part of the polysaccharide challenge phase of
the study, 251 were included in the analysis of persistence of
antibodies following vaccination and 248 in the post challenge
immunogenicity analysis. Reasons for non inclusion in each phase
of the study are specified in Figure 1.
Approximately one quarter of the infants’ mothers had received
a meningococcal vaccine during the year preceding the infant’s
vaccination (38/140 vs. 37/140 for the study vaccine and the
control vaccine groups respectively).
Immunogenicity
One month after the third dose of vaccine had been given, the
lower limits of 95% CI of differences between groups in
seroprotection rates (for diphtheria, tetanus, hepatitis B, Hib) or
the upper limit of the 95% CI of the group ratio of GMC (for
pertussis) were all within the pre-determined criteria for non-
inferiority (Table 2). The new heptavalent combination was
therefore non-inferior to the currently available pentavalent
vaccine for the five antigens common to the two vaccines. The
immune responses to tetanus and PRP antigens (GMCs) were
higher in infants who received the study vaccine than in those who
received the control vaccine (Figure 2).
The lower limit of the 95%CI of the percentages of infants with
SBA-MenA and SBA-MenC titres of at least 1:8 was well above
the pre-set criterion of 80%, demonstrating the immunogenicity of
the MenA and MenC conjugate antigens in the new candidate
vaccine (Table 2). The proportion of infants with SBA-MenA
titres $ 1:8 was significantly higher in the study vaccine group
than in the control group : 88.2% (95%CI [80.4–93.8]) vs 7.6%
(95%CI [3.7–13.6]) (Table 3). Similarly, the proportion of infants
having SBA-MenC titres $1:8 was significantly higher in the
study vaccine group than in the control group: 87.8% (95%CI
[80.7–93.0]) vs 8.6% (95%CI [4.4–14.9]). All subjects in the study
group had anti-PSA and anti-PSC concentrations $0.3 mg/ml
(Table 3) one month after the third dose. 94.9% and 96.7% of
children in the study vaccine group had anti-PSA and anti-PSC
concentrations respectively of at least 2.0 mg/ml (data not shown).
Analysis of immunogenicity according to pre-vaccination status
showed that one month after administration of the third dose of
meningococcal conjugate vaccine SBA MenC and SBA MenA
GMTs were lower in infants with pre-existing bactericidal
antibodies (S+) compared to those with no pre-existing bacteri-
cidal antibodies S- (S+ 150.7; 95%CI [89.0–255.2], S- 704.5; 95%
CI [412.7–1202.4] and S+ 54.9; 95% CI [31.7–95.2], S- 80.2;
95% CI [56.9–113.1]) for serogroup C and serogroup A
antibodies respectively. Although 95% confidence limits over-
lapped for both assays, anti-PSC GMCs tended to be higher in S-
subjects (23.54 mg/ml; 95%CI [15.94–34.76]) than in S+ subjects
(S+) (13.72 mg/ml; 95%CI [11.55–16.30]), whereas anti-PSA
GMCs were within the same range: 8.19 mg/ml; 95%CI [5.67–
11.83] in S- and 6.27 mg/ml; 95%CI [5.35–7.35] in the S+
subjects.
Prior to challenge with MenA and MenC polysaccharides,
47.7% and 56.4% of subjects in the study group had SBA-MenA
and SBA-MenC antibody titers $1:8 respectively compared with
25.7% and 5.1% of children in the control group (Figure 3).
Persistence of antibodies to the other antigens present in each
vaccine was within the same range as in the control group
(Figure 4). One month after polysaccharide challenge, SBA-MenA
and SBA-MenC GMTs in children in the study vaccine group
increased 14.0 and 18.8-fold respectively compared with 3.8 and
1.9-fold increases in children in the control group. The
percentages of subjects with SBA titres $1:8 following challenge
were significantly higher in children in the study group (93.5% for
MenA and 88.5% for MenC) than in those in the control group
(51.4% for MenA and 18.2% for MenC)(Table 4).
Reactogenicity and safety
Incidences of reported symptoms following primary vaccination
were similar in both groups, (Figure 5A) with .99% of doses
apparently causing symptoms. Most doses caused pain at the
injection site (.97%) in both groups, but none were graded 3. The
study vaccine tended to induce more episodes of swelling .30 mm
than the control vaccine (23.7% of doses vs. 14.1%, no
overlapping of the 95%CI) but in all such cases swelling resolved
within 9 days. The most prevalent general symptoms solicited
were irritability and fever (Figure 5A). Fever .39uC occurred
following 2.9% (95%CI [1.5–5.1]) of doses of the study vaccine
and following 1.7% (95%CI[0.7–3.4]) of doses of the control
vaccine. Only one child had fever .40uC (after the third dose of
the DTPw-HBV/Hib-MenAC vaccine), and this lasted for only
one day.
Unsolicited adverse events reported following primary vaccina-
tion showed a similar pattern in each group: 99 malaria episodes in
79 subjects were reported in the study vaccine group (within
30 days following vaccination) compared to 110 malaria episodes
in 84 subjects in the control group, but most cases were not
confirmed by microscopy. Other frequent, unsolicited adverse
events were respiratory infections (82 vs. 82), injection site
erythema (65 vs. 61), and diarrhoea (46 vs. 33) in the study and
control vaccine groups respectively.
The percentage of subjects with unsolicited adverse events
reported within 31 days following the administration of the
DTPw-HBV/Hib-MenAC vaccine
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groups (55.1% in the vaccine group and 55.5% in the control
group). Most adverse events were infectious diseases such as
malaria, upper respiratory tract infections and dysentery, but none
of these unsolicited events was considered causally related to
vaccination. Grade 3 unsolicited symptoms were reported only
infrequently in both groups (only three subjects): all 3 subjects had
malaria (1 in the study vaccine group; 2 in the control group), one
Figure 1. Study profile. Footnote: ATP: according to protocol; SIDS: sudden infant death syndrome; ** number of subjects with the elimination
code assigned excluding subjects who have been assigned a lower elimination code number.
doi:10.1371/journal.pone.0002159.g001
DTPw-HBV/Hib-MenAC vaccine
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(control group).
A total of fifty-nine SAEs were reported throughout the study-
37 in subjects who had received the study vaccine and 22 in
subjects who had received the control vaccine. None of the SAEs
was considered by the investigators or the IDMC to be related to
vaccination. Thirteen of the SAEs were reported during the
primary vaccination phase of the study (Figure 5B), 11 in subjects
in the study vaccine group and 2 in the control group. Three
deaths were reported (dysentery+impetigo+septicaemia, aspiration
pneumonia, and sudden infant death syndrome) among subjects in
the study vaccine group. The diagnoses of sudden infant death
syndrome and dysentery+septicemia were made by verbal autopsy,
while the third subject died during hospitalization. The 10 non-
fatal cases with SAEs were all hospitalized and recovered: 8 were
laboratory-confirmed cases of malaria (with or without complica-
tions including a respiratory tract infection, typhoid fever or
enteritis). One child had broncho-pneumonia and one gastroen-
teritis. During the period from the end of the primary vaccination
phase up to administration of the challenge dose of polysaccharide
vaccine a further 38 SAEs were recorded. Twenty-two SAEs
(including 1 death due to malaria, anaemia, bronchopneumonia
and dehydration) were reported in the study vaccine group and 16
(including 3 deaths-2 due to malaria and 1 due to gastro-enteritis
and dehydration) were reported in the control group. During the
month after challenge a further 8 SAEs (all non-fatal) were
reported; these were equally distributed between the study and
the control groups. All except one non-fatal SAE resolved. The
one exception occurred in a child with a history of head injury
who had tonic convulsion secondary to malaria 13 days after
receiving the second vaccine dose as well as a respiratory tract
infection. The child recovered but developed epilepsy and
discontinued the study.
Discussion
This study has shown that both the MenA and MenC conjugate
antigens present in the novel DTPw-HBV/Hib-MenAC combi-
nation vaccine candidate are immunogenic and induce bacteri-
cidal antibody titres $1:8 in close to 90% of infants compared to a
prevalence of less than 10% prevalence in unvaccinated control
infants. High levels of immunity to serogroup A exist in
populations living in the ‘‘meningitis belt’’ [39,40]. Carriage of
meningococci of serogroup A and C was reported to be low in
Burkina Faso, [40,41] although a study reported 17% carriers in
Nigeria [42]. The high level of bactericidal antibodies in our study
may be due to either cross-reacting antibodies or vaccination since
a large segment of the population is routinely vaccinated with
meningococcal polysaccharide vaccine. Thus, the presence of
bactericidal antibodies (SBA titre $1:8) in a substantial proportion
of infants before vaccination (44–48% of infants had SBA-MenC,
25–28% had SBA-MenA titres at this level) is not surprising,
probably reflecting the transfer of maternally derived antibody.
The proportion of infants in the control vaccine group with titres
above this level fell during the following months reflecting a
natural decline in maternally acquired antibody. In contrast,
bactericidal antibody titres persisted in infants who had received
the study vaccine and at 12 months of age, approximately half of
them still had SBA titres $1:8 for each serogroup. The higher
prevalence of anti-PSA (78%) and anti-PSC (75%) maternal
antibodies compared to bactericidal antibodies prior to vaccina-
tion suggest that not all meningococcal antibodies transferred by
the mother to her infant are bactericidal. When mothers were
asked whether they had been vaccinated against meningitis in the
year preceding the start of the study, approximately one quarter of
them remembered being vaccinated; the protective immune
Table 1. Demographic profile of infants in the study and
control groups.
DTPw-HBV/Hib-
MenAC (study
vaccine) (N=140)
DTPw-HBV/Hib
(control)
(N=140)
Mean age (6 SD) at first
vaccination (in weeks)
6.3 (6 0.47) 6.4 (6 0.56)
Females/males 74/66 72/68
Mean height (6 SD) (in cm) 54.5 (6 2.50) 55.0 (6 2.49)
Mean weight (6 SD) (in kg) 4.4 (6 0.59) 4.5 (6 0.65)
doi:10.1371/journal.pone.0002159.t001
Table 2. Primary objectives: inferential sequential analysis 1 month after the third vaccine dose (primary ATP cohort for
immunogenicity)
Co-primary endpoints Pre-set, non-inferiority criteria Values (95%CI)
SBA-MenA $1:8 LL
# seropositivity rate .80% 88.2 (80.4, 93.8)
SBA-MenC $1:8 LL
# seropositivity rate .80% 87.8 (80.7, 93.0)
Anti-PRP $1 mg/ml LL
# group difference .210% 8.18 (1.76, 15.26)
Anti-tetanus $0.1 IU/ml LL
# group difference .210% 0.00 (23.08, 2.87)
Anti-diphtheria $0.1 (ELISA) or 0.016 (Verocell) IU/ml LL
# group difference .210% 20.81 (24.46, 2.05)
Anti-BPT concentration LL
# group ratio of adjusted GMCs
{ .0.67 0.86 (0.73, 1.00)
Anti-HBs $10 mIU/ml LL
# group difference .210% 0.63 (27.94, 9.05)
Note : antigens sequenced by priority
PRP=polyribosylribitol phosphate; BPT=Bortedella pertussis ; HBs=Hepatitis B surface antigen
#Lower limit of the 95% CI
{Adjusted GMC=GMC adjusted for baseline concentration using ANCOVA model
Seropositivity rate=% subjects above cut-off
Group difference=% subjects in vaccine group above cut-off-% subjects in control group above cut-off
Group ratio=GMC vaccine group/GMC control group
doi:10.1371/journal.pone.0002159.t002
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known to last for at least 3 years [43,44]. Vaccination against
meningitis is undertaken repeatedly in Northern Ghana and this
could explain the high background prevalence of anti-PSA and
anti-PSC seropositivity in our study.
MenA and Men C bactericidal antibody titres were lower in
Ghanaian infants than those obtained in a similar study
undertaken in the Philippines where 97.7 and 99% of vaccinated
infants had SBA titres $1:8 for Men A and Men C respectively;
GMTs were 316.7 (95%CI [251.4–398.9]) and 3132.6 (95%CI
[2496.9–3930.1]) for serogroups A and C respectively [30]. The
present study was conducted in a tropical country but the cold-
chain was closely monitored and there were no major deviations of
the temperature at which the vaccines were kept (2–8uC). The
immune response to the other antigens in the combined vaccine
was as expected, so it is highly improbable that an undetected
break in the cold-chain occurred. Another possibility that was
considered was that the immune response of Ghanaian infants to
the meningococcal conjugates might have been suppressed by high
antibody concentrations in their mothers induced by natural
exposure to meningococci or by vaccination. Therefore, the
influence of infants’ pre-vaccination antibody status (SBA-MenA,
SBA-MenC, anti-PSA, anti-PSC) on the immune response to the
new vaccine was studied. The response to the MenC component
of the study vaccine was lower in infants seropositive for SBA-
MenC or anti-PSC prior to vaccination, as has been found in the
United Kingdom with the meningococcal serogroup C conjugate
vaccine [45]. In contrast to MenC, pre-existing anti-MenA
antibodies did not influence the immune response to the MenA
component of the vaccine. Another possible reason for the lower
immunogenicity seen in the present trial compared with the one
undertaken the Philippines might be the very high level of pre-
existing anti-TT antibodies found in the prevaccination samples of
Ghanaian infants in the study vaccine and control groups (93%
and 97% respectively) resulting from the fact that most women
had been vaccinated against tetanus during pregnancy following
the recommendation of the WHO [46]. However, a negative
impact of pre-existing anti-TT antibodies on the MenAC response
(the MenAC conjugate uses TT as a carrier) is unlikely as the anti-
PRP response was higher in infants who received the study vaccine
Figure 2. Reverse cumulative curves for antibody concentration/titre, 1 month after the third dose of vaccine (Primary ATP cohort
for immunogenicity). Footnote: HibMenAC=DTPw-HBV/Hib-MenAC; Control=DTPw-HBV/Hib.
doi:10.1371/journal.pone.0002159.g002
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Hib conjugate also uses a tetanus carrier. This effect was seen even
though the quantity of PRP used in the study vaccine was 4 times
less than in the control, probably as a result of a TT carrier effect
as reported previously [21,47]. Other possible explanations for the
lower immunogenicity of the MenA and MenC components of the
candidate vaccine in Ghanaian infants are malnutrition and
malaria. Cases of malnutrition were excluded at study entry and
no serious episodes of malnutrition were reported during the
primary vaccination phase of the study. Malaria can suppress the
response to many vaccines including Hib conjugate vaccines and
meningococcal polysaccharide vaccines [48,49] but malaria is
relatively uncommon in the first six months of life, even in areas of
high transmission. Malaria was reported in about half of the study
infants during the primary vaccination phase of this study but, in
most cases, diagnosis was not confirmed by microscopy. Further
research may be needed to determine if malaria influences the
immune response to the meningococcal conjugate antigens.
Non-inferiority of the DTPw-HBV/Hib-MenAC vaccine com-
pared to the control vaccine was demonstrated for the five antigens
common to each vaccine. Although seroprotection for hepatitis B
was in the lower range of that found in published studies, it is
comparable to that induced by the control vaccine and remains at
an acceptable level given that no hepatitis B vaccine was
administered at birth and that similar levels of protection have
been seen previously following immunization with a hepatitis B
monovalent vaccine in other African countries using the same
immunization schedule [50].
The reactogenicity of DTPw-HBV/Hib-MenAC was similar to
that of the control vaccine. The trend to more marked swelling at
the injection site was without consequence and did not lead to any
drop-outs. Three deaths reported in the study group within one
month of primary vaccination were unrelated to the vaccine.
These deaths, which occurred during the rainy season, when
mortality is highest, are fewer than expected in a cohort of 280
children followed to the age of 7 months in a community with an
infant mortality rate of 95.5/1000 [51]. One infant abandoned the
study after a malaria episode followed by epilepsy; there is now
good evidence that malaria increases the risk of epilepsy [52].
Although most SAEs during the primary vaccination phase of the
trial were in the study vaccine group (11 vs. 2), the pattern of SAEs
was that of common infections in this community, such as malaria
and acute respiratory infections, and none of the events were
considered to be vaccine related. The occurrence of a higher
incidence of SAEs in the study than in the control group was
probably a result of chance as evidenced by a more extended
safety follow-up that was done up to the end of the challenge phase
which did not reveal a difference in the overall incidence of SAEs
between the groups. Furthermore, in a large safety study including
1780 infants vaccinated with either the DTPw-HBV/Hib-MenAC
or the DTPw-HBV/Hib vaccines in Asia, the incidence of SAEs
was similar in both groups [51]. Nevertheless, the safety of the new
Table 3. Seropositivity/seroprotection rates and GMTs/GMCs before and 1 month after primary vaccination (ATP cohort for the
primary immunogenicity study)
Study vaccine* Control vaccine**
Antibody
Timepoint to
vaccination N
% subjects with titres/
concentrations $ cut-off
(95% CI)
GMT or GMC
(95% CI) N
% subjects with titres/
concentrations $
cut-off (95% CI) GMT or GMC (95% CI)
SBA-MenA Pre 112 27.7 (19.6,36.9) 8.4 (6.5, 10.8) 122 24.6 (17.2, 33.2) 7.4 (6.0, 9.3)
Post-dose III 102 88.2 (80.4, 93.8) 65.0 (49.4, 85.6) 131 7.6 (3.7, 13.6) 5.2 (4.4, 6.2)
SBA-MenC Pre 118 47.5 (38.2, 56.9) 17.2 (12.5, 23.6) 118 44.1 (34.9, 53.5) 14.3 (10.7, 19.1)
Post-dose III 123 87.8 (80.7, 93.0) 327.5 (223.9, 479.0) 128 8.6 (4.4, 14.9) 5.0 (4.3, 5.8)
Anti-PSA Pre 108 75.0 (65.7, 82.8) 0.9 (0.7, 1.2) 115 75.7 (66.8, 83.2) 0.9 (0.7, 1.15)
Post-dose III 118 100.0 (96.9, 100.0) 6.4 (5.5, 7.4) 127 24.4 (17.2, 32.8) 0.2 (0.2, 0.3)
Anti-PSC Pre 108 77.8 (68.8, 85.2) 1.0 (0.8, 1.3) 118 78.0 (69.4, 85.1) 1.0 (0.8, 1.2)
Post-dose III 122 100.0 (97.0, 100.0) 15.5 (13.4, 17.9) 127 34.6 (26.4, 43.6) 0.3 (0.2, 0.3)
Anti-PRP Post-dose III 119 100.0
(1) (96.9, 100) 14.9 (11.8, 18.9) 130 97.7
(1) (93.4, 99.5) 7.4 (5.6, 9.8)
96.6
(2) (91.6, 99.1) 88.5
(2) (81.7, 93.4)
Anti-tetanus Pre 102 93.1 (86.4, 97.2) 1.0 (0.7, 1.2) 110 97.3 (92.2, 99.4) 0.9 (0.8, 1.2)
Post-dose III 121 100.0 (97.0, 100.0) 3.4 (2.9, 4.1) 130 100.0 (97.2, 100.0) 2.1 (1.7, 2.5)
Anti-diphtheria Post-dose III 123 99.2{ (95.6, 100.0){ 1.2 (1.0, 1.4){{ 131 100.0{ (97.2, 100.0){ 1.3 (1.1, 1.5){{
Anti-BPT Post-dose III 125 98.4 (94.3, 99.8) 132.9 (117.4, 150.5) 132 100.0 (97.2, 100.0) 160.8 (147.4, 175.5)
Anti-HBs Post-dose III 117 88.0 (80.7, 93.3) 131.4 (94.4, 183.0) 127 87.4 (80.3, 92.6) 218.1 (159.8, 297.5)
*DTPw-HBV/Hib-MenAC
**DTPw-HBV/Hib
PSC/A=serogroup S/A polysaccharide ; PRP=polyribosylribitol phosphate; BPT=Bortedella pertussis ; HBs=Hepatitis B surface antigen
Dilution titre (SBA), mg/ml (anti PSA/C, anti PRP), IU/ml (anti–tetanus and anti-diphtheria), EL U/ml (anti-BP), mIU/ml (anti-HBs).
(1): anti PRP $ 0.15 mg/ml ;
(2): anti PRP $ 1.0 mg/ml
{$0.1IU/ml by ELISA or $ 0.016IU/ml by VERO cell neutralisation test when concentration by ELISA,0.1IU/ml (seroprotection);
{{: by ELISA
N=number of subjects with available results; Pre=pre-primary vaccination; Post-dose=1 month post-dose 3
95% CI=95% confidence interval
GMT/GMC=geometric mean antibody titre/concentration calculated on all subjects
doi:10.1371/journal.pone.0002159.t003
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similar increase in SAEs was seen in a previous study that
evaluated another meningococcal conjugate vaccine in Africa,
although this was also considered to be most likely to be a result of
chance [27].
Because the age distribution of cases of meningococcal disease
in Africa covers a broader range than Hib or pneumococcal
infections in children, introduction of the new vaccine into the EPI
program would, alone, have only a limited impact on the overall
burden of meningococcal disease until vaccination had been
continued for many years. Recent experience in the UK with a
MenC conjugate suggests that immunization in infancy gives only
short-term direct protection and that a booster dose is required to
provide sustained immunity [22]. Additional complementary
vaccination strategies are needed in addition to infant immuniza-
tion if a maximum effect is to be achieved. Vaccination of all
children and young adults with a monovalent group A conjugate,
or even better with a tetravalent ACWY conjugate, is a possible
way of achieving this using infant immunization to maintain the
pool of protected individuals.
Figure 3. Persistence of meningococcal antibody responses. Seropositivity rates and GMTs/GMCs after primary vaccination (Post-dose III) and
before the polysaccharide challenge (Pre-challenge) (ATP cohort for persistence). Footnote: Error bars represent 95%CI.
doi:10.1371/journal.pone.0002159.g003
Figure 4. Seropositivity/seroprotection rates for other antigens (D*, T, P, HBV) after primary vaccination (Post-dose III) and before
the polysaccharide challenge (Pre-challenge) (ATP cohort for persistence for diphtheria, ATP cohort for immunogenicity for post-
dose III). Footnote: Error bars represent 95%CI.
doi:10.1371/journal.pone.0002159.g004
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inferior to the control vaccine in inducing antibody titres that are
associated with protection against 5 important childhood diseases
in a single series of injections given during the routine vaccination
EPI schedule. The vaccine induces bactericidal antibody titres
which should provide protection against infection with group A
and group C meningococci in infants in the ‘‘meningitis belt’’
during the first year of life. However, induction of more sustained
protection will require booster immunization given routinely or
perhaps through mass vaccination campaigns. Introduction of this
combined conjugate vaccine into the routine immunization
programme of countries within the meningitis belt could be an
important option towards lowering the burden due to recurrent N.
meningitidis epidemics in Africa.
Supporting Information
Protocol S1 Trial Protocol
Found at: doi:10.1371/journal.pone.0002159.s001 (0.80 MB PDF)
Checklist S1 CONSORT Checklist
Found at: doi:10.1371/journal.pone.0002159.s002 (0.05 MB
DOC)
Acknowledgments
The authors would like to thank all the infants and their families as well as
the health care personnel that participated in this study and the local
authorities in Navrongo. The authors are indebted to Marie-Paule Kieny
(WHO-Geneva) for protocol and data review, to John Williams (Navrongo
Health Research Center, Navrongo,Ghana) for medical monitoring, to
Lawrence Yamuah (WHO-Ethiopia) for study monitoring, to Gerd
Pluschke (Swiss Tropical Institute, Basel, Switzerland) for help in the
implementation of the study on site, to Oscar Bangre (Navrongo Health
Research Center, Navrongo,Ghana) for assistance with implementation of
the study on site and data cleaning, to Vale ´rie Marichal (M-Source,
Rixensart, Belgium) for central study coordination, to Jan Poolman and
Isabel De Vleeschauwer (GSK Biologicals, Rixensart, Belgium) for the
serological assays and data review, to Christelle Durand (GSK Biologicals,
Rixensart, Belgium) and Lieven Declercq (IDMC) for statistical support, to
Jean-Luc Lie ´nard (XpePharma, Belgium) who contributed to technical
Table 4. Seropositivity rates and GMTs/GMCs before (pre-challenge) and 1 month after (post-challenge) a polysaccharide
challenge dose had been given (booster ATP cohort for immunogenicity)
Study vaccine* Control vaccine**
Antibody
Timepoint to
vaccination N
Seropositivity
(%) (95% CI)
GMT or GMC
95% CI) N
Seropositivity(%)
$ 1: 8 (95% CI)
GMT or GMC
(95% CI)
SBA-MenA Pre-challenge 109 47.7 (38.1, 57.5) 27.8 (18.2, 42.3) 103 25.2 (17.2, 34.8) 12.2 (8.3, 18.1)
Post-challenge 107 93.5 (87.0, 97.3) 390.1 (280.2, 543.0) 109 51.4 (41.6, 61.1) 46.4 (28.8, 74.7)
SBA-MenC Pre-challenge 117 56.4 (46.9, 65.6) 31.6 (21.9,45.8) 116 5.2 (1.9, 10.9) 4.6 (4.0, 5.1)
Post-challenge 122 88.5 (81.5, 93.6) 593.5 (398.1, 884.7) 121 18.2 (11.8, 26.2) 8.7 (6.2, 12.3)
Anti-PSA Pre-challenge 115 23.5 (16.1, 32.3) 0.21 (0.19, 0.24) 115 5.2 (1.9, 11.0) 0.16 (0.15, 0.17)
Post-challenge 120 90.8 (84.2, 95.3) 4.72 (3.41, 6.52) 117 47.0 (37.7, 56.5) 0.38 (0.30, 0;48)
Anti-PSC Pre-challenge 116 78.4 (69.9, 85.5) 0.62 (0.52, 0.73) 113 4.4 (1.5, 10.0) 0.17, (0.15, 0.18)
Post-challenge 119 98.3 (94.1, 99.8) 4.29 (3.57, 5.14) 121 100 (97.0, 100) 3.58 (3.03, 4.24)
*DTPw-HBV/Hib-MenAC
**DTPw-HBV/Hib
PSA/C=serogroup A/C polysaccharide ; % subjects=percentage of subjects with seroprotective/seropositive titre/concentration of at least 1:8 (SBA-MenA/C), 0.3 mg/ml
(anti PSA/C), 95% CI=95% confidence interval
GMT/GMC=geometric mean antibody titre/concentration calculated on all subjects.
doi:10.1371/journal.pone.0002159.t004
Figure 5. Incidence of adverse events. A: Solicited local and general symptoms within the 4-day period after vaccination. Footnote: Error bars
represent 95%CI. B: SAEs distribution over time in the total vaccinated cohort. HibMenAC: DTPw-HBV/Hib-MenAC (study vaccine); Control : DTPw-
HBV/Hib (control vaccine)
doi:10.1371/journal.pone.0002159.g005
DTPw-HBV/Hib-MenAC vaccine
PLoS ONE | www.plosone.org 10 May 2008 | Volume 3 | Issue 5 | e2159writing aspects and to Laurence Rouxhet (GSK Biologicals, Rixensart,
Belgium), Erik Michels (XpePharma, Belgium) and Caterina Hatzifoti
(XpePharma, Belgium) for publication coordination.
The authors also thank the Independent Data Monitoring Committee
(IDMC) Members: Blaise Genton (University of Lausanne, Switzerland),
Paul Coleman (London School of Hygiene and Tropical Medicine,
London, UK), Kalifa Bojang (Medical Research Council, The Gambia)
and George Amofah (Ministry of Health, Accra, Ghana).
Professor Brian Greenwood confirms that authors had full access to all
data of the study, and acts as a guarantor for the analysis presented.
Author Contributions
Conceived and designed the experiments: BG DC AF ZR DB AH FB CB.
Analyzed the data: BG DC AF ZR DB AH FB CB. Contributed reagents/
materials/analysis tools: BG DC AF ZR DB AH FB CB. Wrote the paper:
BG DC AF ZR DB AH FB CB.
References
1. Epidemics of meningococcal disease, African meningitis belt (2001) WHO,
Weekly Epidemiological Record 76: 282–288.
2. Lapeysonnie L (1963) La meningite ce ´re ´brospinale en Afrique. Bull WHO 28:
S3–114.
3. Greenwood B (1999) Manson Lecture. Meningococcal meningitis in Africa.
Trans R Soc Trop Med Hyg 93: 341–353.
4. Vergano S, Heath P (2003) Neisseria meningitis serogroup A vaccines: an
overview. Expert Rev Vaccines 2: 571–582.
5. Tikhomirov E, Santamaria M, Esteves K (1997) Meningococcal disease: public
health burden and control. World health Stat Q 50: 170–177.
6. Balmer P, Miller E (2002) Meningococcal disease: how to prevent and how to
manage. Curr Opin Infect Dis 15: 275–281.
7. Enhanced surveillance of epidemic meningococcal meningitis in Africa: a three-
year experience (2005) WHO, Weekly Epidemiological Record. 80: 313–320.
8. Campagne G, Schuchat A, Djibo S, Ousse ´ini A, Cisse ´ L, et al. (1999)
Epidemiology of bacterial meningitis in Niamey, Niger, 1981-96. Bull WHO 77:
499–508.
9. Nathan N, Borel T, Djibo A, Evans D, Djibo S, et al. (2005) Ceftriaxone as
effective as long-acting chloramphenicol in short-course treatment of meningo-
coccal meningitis during epidemics: a randomised non-inferiority study. Lancet
366: 308–313.
10. WHO: control of epidemic meningococcal disease (1998) WHO practical
guidelines. 2nd edition (WHO/EMC/BAC/98.3). Available: www.who.int/
emc-documents/meningitis/docs/whoemcbac983.pdf. Accessed 7 April 2006.
11. Lingappa J, Al-Rabeah A, Hajjeh R, Mustafa T, Fatani A, et al. (2001)
Serogroup W-135 disease during the Hajj, 2000. Emerg Infect Dis 9: 665–671.
12. Boisier P, Djibo S, Sidikou F, Mindadou H, Kairo K, et al. (2005)
Epidemiological patterns of meningococcal meningitis in Niger in 2003 and
2004: under the threat of N. meningitidis serogroup W135. Trop Med Inter
Health 10: 435–443.
13. Njanpop-Lafourcade BM, Parent du Cha ˆtelet I, Sanou O, Alonso JM, Taha MK
(2005) The establishment of Neisseria meningitis serogroup W135 of the clonal
complex ET-37/ST-11 as an epidemic clone and the presence of serogroup A
isolate in Burkina Faso. Microbes Infect 7: 645–649.
14. Meningoccocal disease, Chad–update (2005) WHO, Weekly Epidemiological
Record 80: 113–124.
15. Forgor AA, Leimkugel J, Hodgson A, Bugri A, Dangy JP, et al. (2005)
Emergence of W135 meningococcal meningitis in Ghana. Trop Med Int Health
10: 1229–1234.
16. WHO Regional Office for Africa (2006) MDSC meningitis weekly bulletin, week
27–30 .
17. Greenwood B, Smith A, Hassan-King M, Bijlmer H, Shenton F, et al. (1986)
The efficacy of meningococcal polysaccharide vaccine in preventing group A
meningococcal disease in The Gambia, West Africa. Trans R Soc Trop Med
Hyg Correspondence 80: 1006–1007.
18. WHO fact sheet N 141 (2006) Available: http://www.who.int/mediacentre/
factsheets/fs141/en. Accessed 7 April 2006.
19. Robbins J, Schneerson R, Gotschlich EC, Mohammed I, Nasidi A, et al. (2003)
Meningococcal meningitis in sub-Saharan Africa: the case for mass and routine
vaccination with available polysaccharide vaccines. Bulletin of the World Health
Organization 81: 745–750.
20. Richmond P, Borrow R, Miller E, Clark S, Sadler F, et al. (1999) Meningococcal
serogroup C conjugate vaccine is immunogenic in infancy and primes for
memory. J Infect Dis 179: 1569–1572.
21. Richmond P, Borrow R, Findlow J, Martin S, Thornton C, et al. (2001)
Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid
conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic
priming, and bactericidal activity against O-acetylated and De-O-acetylated
serogroup C strains. Infect Immun 69: 2378–2382.
22. Trotter C, Andrews N, Kaczmarski E, Miller E, Ramsay M (2004) Effectiveness
of meningococcal serogroup C conjugate vaccine 4 years after introduction.
Lancet 364: 365–367.
23. Maiden M, Stuart J (2002) Carriage of serogroup C meningococci 1 year after
meningococcal C conjugate polysaccharide vaccination. Lancet 359:
1829–1831.
24. Pichichero ME (2005) Meningococcal conjugate vaccines. Expert Opinion Biol
Ther 5: 1475–1489.
25. Chippaux JP, Garba A, Ethevenaux C, Campagne G, de Chabalier F, et al.
(2004) Immunogenicity, safety, and memory of different schedules of Neisseria
meningitidis A/C-diphtheria toxoid conjugate vaccine in infants in Niger.
Vaccine 22: 3303–3311.
26. Twumasi P, Kumah S, Leach A, O’Dempsey TJ, Ceesay SJ, et al. (1995) A trial
of a group A plus group C meningococcal polysaccharide-protein conjugate
vaccine in African infants. J Infect Dis 171: 632–638.
27. Leach A, Twumasi P, Kumah S, Banya WS, Jaffar S, et al. (1997) Induction of
immunologic memory in Gambian children by vaccination in infancy with a
group A plus group C meningococcal polysaccharide-protein conjugate vaccine.
J Infect Dis 175: 200–204.
28. MacLennan J, Obaro S, Deeks J, Williams D, Pais L, et al. (2001) Immunologic
memory 5 years after meningococcal A/C conjugate vaccination in infancy.
J Infect Dis 183: 97–104.
29. Meningitis Vaccine Project Available: http://www.meningvax.org/. Accessed 7
April 2006.
30. Gatchalian S, Palestroque E, De Vleeschauwer I, Han HH, et al. (2007) The
development of a new heptavalent diphtheria-tetanus-whole cell pertussis-
hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A
and C vaccine: a randomized dose-ranging trial of the conjugate vaccine
components. Int J Infect Dis (in press).
31. National AIDS/STI Control Programme (2007) HIV Sentinel Survey 2006
Report, Republic of Ghana and Ghana Health Services: p 52.
32. Leimkugel J, Hodgson A, Forgor AA, Pflu ¨ger V, Dangy JP, et al. (2007) Clonal
waves of neisseria colonization and disease in the African meningitis belt: Eight
year longitudinal study in Northern Ghana. PLoS Med 4(3): e101. doi10.1371/
journal.pmed.0040101.
33. Ghana’s Expanded Programme on Immunization in Ghana. Available: http://
www.who.int/countries/gha/publications/EPI_Profile.pdf. Accessed 7 April
2006.
34. Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, et al.
(1997) Standardization and a multilaboratory comparison of Neisseria
meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab
Immunol 4: 156–167.
35. Borrow R, Balmer P, Miller E (2005) Meningococcal surrogates of protection-
serum bactericidal antibody activity. Vaccine 23: 2222–2227.
36. Peltola H (1998) Meningococcal vaccines. Current status and future possibilities
Drugs 55: 347–366.
37. Gheesling LL, Carlone GM, Pais LB, Holder PF, Maslanka SE, et al. (1994)
Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular
polysaccharide antibody levels measured by a standardized Enzyme-Linked
Immunosorbent Assay. J Clin Microbiol 32: 1475–1482.
38. Miyamura K, Nisho S, Ito A, Murata R, Kono R (1974) Micro cell culture
method for determination of diphtheria toxin and antitoxin concentrations using
VERO cells: I. Studies on factors affecting the toxin and antitoxin titration. J Biol
Stand 2: 189–201.
39. Amir J, Louie L, Granoff D (2005) Naturally-acquired immunity to Neisseria
meningitidis group A. Vaccine 23: 977–983.
40. Mueller JE, Yaro S, Traore Y, Sangare L, Tarnagda Z, Njanpop-
Lafourcade BM, Borrow R, Gessner BD (2006) Neisseria meningitidis serogroups
A and W-135: carriage and immunity in Burkina Faso,2003. J Infect. Dis 193:
812–20.
41. Yaro S, Traore ´ Y, Tarnagda Z, Sangare ´ L, NjanpopLafourcade BM, Drabo A,
Findlow H, Borrow R, Nicolas P, Gessner BD, Mueller JE (2007) Meningococcal
carriage and immunity in western Burkina Faso, 2003. Vaccine 25 Suppl 1:
A42–6.
42. Blakebrough IS, Gilles HM (1980) The effect of rifampicin on meningococcal
carriage in family contacts in northern Nigeria. J Infect 2(2): 137–143.
43. Greenwood B, Smith AW, Hassan-King M, Bijmler HA, Shenton FC, et al.
(1986) The efficacy of meningococcal polysaccharide vaccine in preventing
group A meningococcal disease in The Gambia, West Africa. Trans R Soc Trop
Med Hyg 80: 1006–1007.
44. De Wals P, Deceuninck G, De Serres G, Boivin JF, Duval B, et al. (2005)
Effectiveness of serogroup C meningococcal polysaccharide vaccine: results from
a case-control study in Quebec. Clin Infect Dis 40: 1116–1122.
45. Southern J, Crowley-Luke A, Borrow R, Andrews N, Miller E (2005)
Immunogenicity of one, two or three doses of a meningococcal C conjugate
vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination
course in UK infants at 2, 3 and 4 months of age with acellular pertussis-
containing DTP/Hib vaccine. Vaccine 24: 215–219.
46. Immunization policy. Global Programme for vaccines and immunization (1996)
Expanded Program on Immunization. (WHO/EPI/GEN/95.03 Rev 1) p : 19.
Available: http://whqlibdoc.who.int/hq/1995/WHO_EPI_GEN_95.03_REV.
1.pdf. Accessed 7 April 2006.
DTPw-HBV/Hib-MenAC vaccine
PLoS ONE | www.plosone.org 11 May 2008 | Volume 3 | Issue 5 | e215947. Kitchin N, Southern J, Morris R, Hemme F, Thomas S, et al. (2007) Evaluation
of a diphtheria–tetanus–acellular pertussis -inactivated poliovirus–Haemophilus
influenzae type b vaccine given concurrently with meningococcal group C
conjugate vaccine at 2, 3 and 4 months of age. Arch Dis Child 92: 11–16.
48. Usen S, Milligan P, Ethevenaux C, Greenwood B, Mulholland K (2000) Effect
of fever on the serum antibody response of Gambian children to Haemophilus
influenzae type b conjugate vaccine. Pediatr Infect Dis J 19: 444–449.
49. Williamson WA, Greenwood BM (1978) Impairement of the immune response
to vaccination after acute malaria. Lancet 311: 1328–1329.
50. Aspinall S, Kocks D (1998) Immunogenicity of a low-cost hepatitis B vaccine in
the South African Expanded Programme on Immunisation. S Afr Med J 88:
36–39.
51. Nyarko P, Wontuo P, Wak G, Chirawurah D, Welaga P, et al. (2001) The
Navrongo demographic surveillance system 2001 report to the Rockefeller
Foundation. Community health and family planning project documentation
note number 45. Navrongo, Upper East Region, Ghana.
52. Carter JA, Neville BGR, White S, Ross AJ, Otieno G, et al. (2004) Increased
Prevalence of Epilepsy Associated with Severe Falciparum Malaria in Children.
Epilepsia 45: 978–981.
DTPw-HBV/Hib-MenAC vaccine
PLoS ONE | www.plosone.org 12 May 2008 | Volume 3 | Issue 5 | e2159